Las glucogenosis son enfermedades hereditarias del metabolismo del glucógeno. Se reconocen más de 12 tipos y afectan principalmente al hígado y al músculo, by Glycogen storage disease 1b: Speculation on the role of autoimmunity. Tratamiento continuo con factores estimulantes de colonias (G-CSF) de la neutropenia asociada a la glucogenosis tipo IbTreatment with granulocyte colony . A glycogen storage disease (GSD) is the result of an enzyme defect. These enzymes normally catalyze reactions that ultimately convert.

Author: Nikodal Voramar
Country: Namibia
Language: English (Spanish)
Genre: Technology
Published (Last): 24 December 2008
Pages: 184
PDF File Size: 17.72 Mb
ePub File Size: 1.33 Mb
ISBN: 981-5-76682-967-5
Downloads: 19835
Price: Free* [*Free Regsitration Required]
Uploader: Bajas

The pathogenic variants in the G6Pase system cause deficiency of the catalytic activity of the enzyme, thus preventing release of free glucose in the affected tissues liver, kidney, intestinal mucosa.

Glycogen storage disease type I – Wikipedia

Variant designation that does not conform to current naming conventions. Moses SW, Parvari R. Brain damage in glycogen storage disease type I.

Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Although a liver transplant resulted in the resolution of hypoglycemia it did not however resolve the chronic neutropenia and gkucogenosis risk of infection among patients. Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. Similar articles in PubMed. Impaired platelet aggregation is an uncommon effect of chronic hypoglycemia.

Glycogen Storage Disease Type I – GeneReviews® – NCBI Bookshelf

Other family members of a proband. Hence, the classification of GSDI into four subtypes no longer exists. The disease is more common in Ashkenazi Jewish populations, people of Mexican, Chinese, and Japanese descent. Lipid-lowering drugs may also lead to adverse fetal effects and should be avoided during pregnancy.


The lack of either G6Pase catalytic activity or glucosephosphate exchanger SLC37A4 transporter activity in the liver leads to inadequate conversion of glucosephosphate into glucose through normal glycogenolysis and gluconeogenesis pathways, resulting in severe hypoglycemia and many other signs and symptoms of the GSDI disorders.

Tests in GTR by Gene. Intestinal function in glycogen storage disease type I. Evaluation of relatives at risk: Deficient hepatic enzyme activity glucosephosphatase catalytic activity or glucosephosphate exchanger SLC37A4 activity from a liver biopsy specimen establishes the diagnosis if molecular genetic testing is inconclusive.

Intestinal involvement can cause mild malabsorption with steatorrhea, greasy stools, but usually requires no treatment. Frequent or continuous feedings of cornstarch or other carbohydrates are the principal treatment.

Glycogen storage disease type I

Family planning The optimal time for determination of genetic risk, clarification lgucogenosis carrier status, and discussion of the availability of prenatal testing is before pregnancy. Thus glucosephosphatase mediates the final, key, step in both of the two main processes of glucose production during fasting.

This issue should be addressed when reviewing the clinical history of glicogenosis females with GSDI. Intake of carbohydrates which must be converted to G6P to be utilized e. Some individuals treated early develop hepatic adenoma and proteinuria in adulthood. Changes in IQ, MRI findings, and EEG were found to correlate with the frequency of hypoglycemic episodes, particularly in those in poor dietary compliance [ Melis et al ]. Tipl for a relationship between poor metabolic control and the development of adenomas is conflicting [ Di Rocco et alWang et alKishnani et alBeegle et al ].

Diagnostic methods Diagnosis is gljcogenosis on clinical presentation, and glycemia and lactacidemia levels, after a meal hyperglycemia and hypolactacidemiaand after three to four hour fasting hypoglycemia and hyperlactacidemia. Those at highest risk typically have a coexisting condition that also predisposes them to developing pulmonary hypertension [ PizzoFurukawa et alHamaoka et alBolz et alKishnani et al ].


Epub May Glucosephosphatase G6Pase catalytic activity. Glycogen also accumulates in kidneys and small intestine. However, further studies are needed to investigate the long-term efficacy of this approach [ Lee et alRibes-Koninckx et al ].

Molecular Genetic Testing Molecular testing approaches can include serial single- gene testing, targeted analysis for pathogenic variants tiop, use of a multigene ttipoand more comprehensive genomic testing: Type I glycogen storage disease with focal nodular hyperplasia of the liver and vasoconstrictive pulmonary hypertension. For G6PC pathogenic variant p. Administration of glucagon or epinephrine causes little or no increase in blood glucose concentration, but both increase serum lactate concentrations significantly.

The inability to generate and release glucose soon results in hypoglycemia, and occasionally in lactic acidosis fulminant enough to appear as a primary respiratory problem in the newborn period. Once the diagnosis has been made, the principal goal of treatment is to maintain an adequate glucose level and prevent hypoglycemia. Hypovitaminosis D in glycogen storage disease type I. Bone mineral content can be significantly reduced even in prepubertal children [ Schwahn et alVisser et al bWolfsdorfRake et alCabrera-Abreu et al ].

The liver edge is often at or below the level of the umbilicus.